查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676156

全球转甲状腺素蛋白淀粉样变性治疗市场研究报告-产业分析、规模、份额、成长、趋势与预测 2025 年至 2033 年

Global Transthyretin Amyloidosis Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 232 Pages | 商品交期: 最快1-2个工作天内

价格

全球转甲状腺素蛋白淀粉样变性治疗市场规模预计将从 2024 年的 673 万美元增长到 2033 年的 1,434 万美元，在 2026 年至 2033 年的预测期内呈现 8.77% 的强劲年复合成长率(CAGR)。

随着对这种罕见疾病的认识和诊断的增加，转甲状腺素蛋白淀粉样变性治疗市场有望大幅成长。转甲状腺素蛋白淀粉样变性 (ATTR) 是一种进行性疾病，其特征是淀粉样蛋白在各种组织中积聚，导致器官功能障碍。 ATTR 的盛行率不断上升，尤其是在老年人口中，推动了对有效治疗方案的需求。随着医疗保健提供者寻求改善患者的治疗效果和生活质量，ATTR 治疗市场预计将蓬勃发展。

技术进步在塑造转甲状腺素蛋白淀粉样变性治疗市场的未来方面发挥着至关重要的作用。药物开发的创新，包括小分子疗法和基因沉默技术，正在增强旨在减少淀粉样蛋白沉积和控制症状的治疗效果。此外，诊断工具的进步使得能够更早发现并更准确地监测疾病，这对于及时介入至关重要。随着製药公司不断投入研发，转甲状腺素蛋白淀粉样变性治疗市场可能会更多地采用新疗法并改善患者管理策略。

此外，对以患者为中心的护理和支持的日益重视正在影响转甲状腺素淀粉样变性治疗市场的成长轨迹。随着患者及其家属对疾病和可用的治疗方案的了解越来越多，对满足医疗和情感需求的全面护理计划的需求也越来越大。这一趋势正在推动医疗保健提供者、患者权益团体和研究人员之间的合作，以开发教育资源和支持网络，为患者在治疗过程中提供帮助。随着市场不断发展，技术、患者参与和整体护理方法的整合将成为成功的关键驱动力。

我们的报告经过精心製作，为客户提供有关各个行业和市场的全面且可操作的见解。每份报告都包含几个关键部分，以确保彻底了解市场格局：

市场概览：市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本节探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准将市场细分为不同的细分市场。该分析强调了每个部分的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本节深入介绍领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，预测特定时期内的市场规模和成长趋势。这包括定量分析和图形表示来说明未来的市场轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前和新兴的市场趋势、技术创新和潜在投资领域。本节提供未来市场发展和成长前景的见解。

目录

第 1 章：前言

  • 报告描述
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究流程
    • 市场研究方法

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：转甲状腺素蛋白淀粉样变性治疗产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业趋势
  • 波特五力分析
  • 市场吸引力分析
    • 按药物类型分析市场吸引力
    • 按疾病类型进行的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 按配销通路进行市场吸引力分析
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料製造商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按药物类型

  • 依药物类型概览
  • 按药物类型进行的历史和预测数据分析
  • 氯苯那敏
  • 派蒂西兰
  • 伊诺特森
  • 其他的

第 6 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：依疾病类型

  • 依疾病类型概览
  • 按疾病类型进行的历史和预测数据分析
  • 遗传性转甲状腺素淀粉样变性
  • 野生型转甲状腺素蛋白淀粉样变性

第 7 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按最终用户

  • 最终用户概览
  • 最终用户的历史和预测数据分析
  • 医院
  • 居家护理
  • 专科诊所
  • 其他的

第 8 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按分销管道

  • 按配销通路概览
  • 按配销通路进行的历史和预测资料分析
  • 医院药房
  • 网路药局
  • 零售药局

第 9 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按地区划分

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概述、历史和预测数据销售分析
    • 北美各细分市场销售分析
    • 北美各国销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概述、历史和预测数据销售分析
    • 欧洲各细分市场销售分析
    • 欧洲各国销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概述、历史和预测数据销售分析
    • 亚太地区分部销售分析
    • 亚太地区国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概述、历史和预测数据销售分析
    • 拉丁美洲各细分市场销售分析
    • 拉丁美洲各国销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概述、历史和预测数据销售分析
    • 中东和非洲分部销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东和非洲其他地区销售分析

第 10 章：转甲状腺素蛋白淀粉样变性治疗公司的竞争格局

  • 转甲状腺素蛋白淀粉样变性治疗市场竞争
  • 伙伴关係/合作/协议
  • 合併与收购
  • 新产品发布
  • 其他进展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Pfizer Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AstraZeneca
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Prothena Corporation Plc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ionis Pharmaceuticals
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bellus Health Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Alnylam Pharmaceuticals Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eidos Therapeutics Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Som Biotech
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Abbvie Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bausch Health Companies Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol Myers Squibb Company GSK Plc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck KGaA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，对于私人公司，可能不予涵盖

Product Code: VMR11219273

Global Transthyretin Amyloidosis Treatment Market size is anticipated to grow from USD 6.73 Million in 2024 to USD 14.34 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 8.77% during the forecast period of 2026 to 2033.

The Transthyretin Amyloidosis Treatment Market is poised for significant growth as awareness and diagnosis of this rare disease increase. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the accumulation of amyloid proteins in various tissues, leading to organ dysfunction. The rising prevalence of ATTR, particularly among aging populations, is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and quality of life, the market for ATTR treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the transthyretin amyloidosis treatment market. Innovations in drug development, including small molecule therapies and gene silencing techniques, are enhancing the efficacy of treatments aimed at reducing amyloid deposits and managing symptoms. Additionally, advancements in diagnostic tools are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the transthyretin amyloidosis treatment market is likely to see increased adoption of novel therapies and improved patient management strategies.

Moreover, the growing emphasis on patient-centered care and support is influencing the transthyretin amyloidosis treatment market's growth trajectory. As patients and their families become more informed about the disease and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Type

  • Tafamidis
  • Patisiran
  • Inotersen
  • Others

By Diseases Type

  • Hereditary Transthyretin Amyloidosis
  • Wild Transthyretin Amyloidosis

By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • COMPANIES PROFILED
  • Pfizer Inc
  • AstraZeneca
  • Prothena Corporation plc.
  • Ionis Pharmaceuticals
  • BELLUS Health Inc.
  • Alnylam Pharmaceuticals Inc
  • Eidos Therapeutics Inc
  • SOM BIOTECH
  • Abbvie Inc.
  • Bausch Health Companies Inc. .
  • Bristol Myers Squibb Company GSK Plc.
  • Merck KGaA
  • Sanofi
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Diseases Type
    • 3.7.3 Market Attractiveness Analysis By End User
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data Analysis By Drug Type
  • 5.3. Tafamidis Historic and Forecast Sales By Regions
  • 5.4. Patisiran Historic and Forecast Sales By Regions
  • 5.5. Inotersen Historic and Forecast Sales By Regions
  • 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISEASES TYPE

  • 6.1. Overview By Diseases Type
  • 6.2. Historical and Forecast Data Analysis By Diseases Type
  • 6.3. Hereditary Transthyretin Amyloidosis Historic and Forecast Sales By Regions
  • 6.4. Wild Transthyretin Amyloidosis Historic and Forecast Sales By Regions

7. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY END USER

  • 7.1. Overview By End User
  • 7.2. Historical and Forecast Data Analysis By End User
  • 7.3. Hospitals Historic and Forecast Sales By Regions
  • 7.4. Homecare Historic and Forecast Sales By Regions
  • 7.5. Specialty Clinics Historic and Forecast Sales By Regions
  • 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data Analysis By Distribution Channel
  • 8.3. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 8.4. Online Pharmacy Historic and Forecast Sales By Regions
  • 8.5. Retail Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE TRANSTHYRETIN AMYLOIDOSIS TREATMENT COMPANIES

  • 10.1. Transthyretin Amyloidosis Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Pfizer Inc
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. AstraZeneca
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Prothena Corporation Plc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Ionis Pharmaceuticals
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Bellus Health Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Alnylam Pharmaceuticals Inc
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Eidos Therapeutics Inc
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Som Biotech
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Abbvie Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Bausch Health Companies Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Bristol Myers Squibb Company GSK Plc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Merck KGaA
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Sanofi
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (Units and USD MN)
  • Tafamidis Market Sales By Geography (Units and USD MN)
  • Patisiran Market Sales By Geography (Units and USD MN)
  • Inotersen Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Analysis By Diseases Type (Units and USD MN)
  • Hereditary Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Wild Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Analysis By End User (Units and USD MN)
  • Hospitals Market Sales By Geography (Units and USD MN)
  • Homecare Market Sales By Geography (Units and USD MN)
  • Specialty Clinics Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Analysis By Distribution Channel (Units and USD MN)
  • Hospital Pharmacy Market Sales By Geography (Units and USD MN)
  • Online Pharmacy Market Sales By Geography (Units and USD MN)
  • Retail Pharmacy Market Sales By Geography (Units and USD MN)
  • Global Transthyretin Amyloidosis Treatment Market Sales By Geography (Units and USD MN)
  • North America Market Analysis (Units and USD MN)
  • United States Market Analysis (Units and USD MN)
  • Canada Market Analysis (Units and USD MN)
  • Mexico Market Analysis (Units and USD MN)
  • Europe Market Analysis (Units and USD MN)
  • Europe Market Estimate By Country (Units and USD MN)
  • United Kingdom Market Analysis (Units and USD MN)
  • France Market Analysis (Units and USD MN)
  • Germany Market Analysis (Units and USD MN)
  • Italy Market Analysis (Units and USD MN)
  • Russia Market Analysis (Units and USD MN)
  • Spain Market Analysis (Units and USD MN)
  • Rest of Europe Market Analysis (Units and USD MN)
  • Asia Pacific Market Analysis (Units and USD MN)
  • China Market Analysis (Units and USD MN)
  • Japan Market Analysis (Units and USD MN)
  • India Market Analysis (Units and USD MN)
  • South Korea Market Analysis (Units and USD MN)
  • Australia Market Analysis (Units and USD MN)
  • South East Asia Market Analysis (Units and USD MN)
  • Rest of Asia Pacific Market Analysis (Units and USD MN)
  • Latin America Market Analysis (Units and USD MN)
  • Brazil Market Analysis (Units and USD MN)
  • Argentina Market Analysis (Units and USD MN)
  • Peru Market Analysis (Units and USD MN)
  • Chile Market Analysis (Units and USD MN)
  • Rest of Latin America Market Analysis (Units and USD MN)
  • Middle East & Africa Market Analysis (Units and USD MN)
  • Saudi Arabia Market Analysis (Units and USD MN)
  • UAE Market Analysis (Units and USD MN)
  • Israel Market Analysis (Units and USD MN)
  • South Africa Market Analysis (Units and USD MN)
  • Rest of Middle East and Africa Market Analysis (Units and USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Transthyretin Amyloidosis Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Transthyretin Amyloidosis Treatment Market Size, By Region (Units and USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Diseases Type
  • Market Attractiveness Analysis By End User
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (Units and USD MN)
  • Tafamidis Market Sales By Geography (Units and USD MN)
  • Patisiran Market Sales By Geography (Units and USD MN)
  • Inotersen Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By Diseases Type (Units and USD MN)
  • Hereditary Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Wild Transthyretin Amyloidosis Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By End User (Units and USD MN)
  • Hospitals Market Sales By Geography (Units and USD MN)
  • Homecare Market Sales By Geography (Units and USD MN)
  • Specialty Clinics Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By Distribution Channel (Units and USD MN)
  • Hospital Pharmacy Market Sales By Geography (Units and USD MN)
  • Online Pharmacy Market Sales By Geography (Units and USD MN)
  • Retail Pharmacy Market Sales By Geography (Units and USD MN)
  • Global Market Sales (Units and USD MN)
  • North America Market Sales (Units and USD MN)
  • Europe Market Sales (Units and USD MN)
  • Asia Pacific Market Sales (Units and USD MN)
  • Latin America Market Sales (Units and USD MN)
  • Middle East & Africa Market Sales (Units and USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.